NCT06432309View on ClinicalTrials.gov

Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

April 25, 2024

Conditions
Parkinson DiseaseEffect of Drug
Interventions
DRUG

Opicapone 50 mg

Evaluate the addition of the COMT-I, Opicapone, to the Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.

DRUG

Duodopa

Evaluate Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.

Trial Locations (1)

44122

University Hospital of Ferrara - Arcispedale Sant'Anna, Ferrara

All Listed Sponsors
lead

University Hospital of Ferrara

OTHER